Similarly, a study by Trock et al. evaluated 635 patients receiving sRT at median PSA of 0.70 ng/ml, sRT patients with ADT at median PSA 0.90 ng/ml and patients with no sRT in case of BCR, assessing prostate cancer-specific survival rates, finding a significantly improved survival rate in patients undergoing sRT vs. no sRT [8]. The gene discussed is BCR; the disease is prostate carcinoma.